CWChester Buchan Whitley

Chester Buchan Whitley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chester Buchan Whitley has a total of 274 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural damage of the cervical spinal cord within and beyond the maximal compression area in mucopolysaccharidosis types I and VI

    by Igor Nestrašil, Christophe Lenglet, Ivan Krasovec, Bryon A Mueller, Alia Ahmed, Monica T Bondy, Ivana Labounková, Thierry Chekouo, Alena Svátková, Chester B Whitley, et al.

    Background: Cervical spinal cord (CSC) compression and myelopathy are frequent, severe complications in mucopolysaccharidosis (MPS) types I and VI. Early detection is critical to prevent irreversible neurological deficits and preserve quality of life. This prospective study aimed to identify quantitative neuroimaging biomarkers of structural CSC damage and myelopathy in MPS I and VI. Methods: Structural and diffusion magnetic resonance imaging (MRI) of the CSC was analyzed in 17 MPS I patients, 3 MPS VI patients (19±7 years), and 19 case-matched healthy controls (20±7 years). CSC macrostructure (cross-sectional area, diameters) and microstructure (fractional anisotropy [FA], radial [RD], mean, axial diffusivities) were evaluated within and beyond the maximal compression areas. Results: MPS patients demonstrated reduced CSC cross-sectional area and anterior-posterior diameter at upper cervical levels, alongside widespread microstructural alterations (lower FA, higher RD) throughout the CSC versus controls (p FDR FDR FDR <0.05). Conclusions: CSC MRI provides candidate neuroimaging biomarkers for early detection and characterization of myelopathy in MPS I and VI. Structural damage extends beyond primary maximal compression areas, highlighting these markers for clinical monitoring and future therapeutic trials.

  • Open Access

    Beyond Detection: Comparing State-Based Newborn Screening Methods for Effective Mucopolysaccharidosis I Diagnosis

    by Rithika Thampy, Nishitha R. Pillai, Michael Evans, Chester B. Whitley, Paul J. Orchard, Matthew Ellinwood, Amy Gaviglio

    Mucopolysaccharidosis type I (MPS I) results in the accumulation of glycosaminoglycans (GAG) and, for the purposes of newborn screening, is differentiated into two forms: severe (Hurler syndrome) versus attenuated (encompassing Scheie and Hurler-Scheie syndromes). MPS I was added to the federal Recommended Uniform Screening Panel for newborn screening (NBS) in 2016, and as of December 2025, 45 of 54 programs in the United States (US) screen for MPS I. Within the newborn screening program, a second-tier analysis of GAG is thought to reduce false-positive rates, particularly through mitigating the detection of pseudodeficiency. However, there have been some concerns that the use of second-tier GAG analysis might inadvertently result in missed detection of attenuated cases. A survey of all US NBS programs was conducted requesting data on the total number of screen-positive NBS results for MPS I as well as the final diagnostic outcome from these results. Diagnostic outcomes after screening were classified as false-positive, pseudodeficiency, severe MPS I, attenuated MPS I, and MPS I of undetermined phenotype. Additionally, information on testing methodologies and dates of MPS I NBS implementation was collected. Responses were obtained from 32 NBS programs. The cohort of screening programs utilizing second-tier blood spot GAG determinations detected a higher proportion of severe cases than those not using this second-tier test (48% vs. 29%). The proportion of attenuated cases remained consistent between both groups (13% vs. 14%). The proportion of pseudodeficiency detection was only slightly lower in the cohort using second-tier GAG analysis (85% vs. 91%). Second-tier GAG analysis appears to reduce the detection of false-positive cases and improves the resolution of severe MPS I cases, though the proportion of pseudodeficiency was only slightly lower compared to the programs that do not use second-tier GAG analysis. Currently, the proportion of attenuated cases is comparable between the two cohorts, but the higher number of “undetermined phenotype” cases may eventually shift the balance toward states not using GAG analysis once the type is determined.

  • Open Access

    Diffusion tensor imaging with free‐water correction reveals distinctions between severe and attenuated subtypes in Mucopolysaccharidosis type I

    by Alena Svatkova, Ofer Pasternak, Julie B. Eisengart, Kyle D. Rudser, Petr Bednařík, Bryon A. Mueller, Kathleen A. Delaney, Elsa G. Shapiro, Chester B. Whitley, Igor Nestrašil

    Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disorder leading to deleterious brain effects. While animal models suggested that MPS I severely affects white matter (WM), whole‐brain diffusion tensor imaging (DTI) analysis was not performed due to MPS‐related morphological abnormalities. 3T DTI data from 28 severe (MPS IH, treated with hematopoietic stem cell transplantation—HSCT), 16 attenuated MPS I patients (MPS IA) enrolled under the study protocol NCT01870375, and 27 healthy controls (HC) were analyzed using the free‐water correction (FWC) method to resolve macrostructural partial volume effects and unravel differences in DTI metrics accounting for microstructural abnormalities. FWC analysis in MPS IH compared to HC revealed higher free‐water fraction (FWF) in all WM regions with increased radial (RD) and mean diffusivity (MD). Higher RD, MD, and FWF in cingulate and FWF in temporal WM were observed in MPS IA relative to HC. FWF and RD in the corpus callosum (CC) were higher in MPS IH than in MPS IA. Reaction time was correlated with fractional anisotropy (FA) in frontal and parietal WM in MPS IH. FA in temporal and central WM correlated with d‐prime in MPS IA. The HSCT age was related to FA in parietal WM and FWF in frontal WM in MPS IH. FWC delineated subtype‐specific WM microstructural abnormalities linked to myelination that were more extensive in MPS IH than IA, with CC findings being a key differentiator between subtypes. Earlier age at HSCT was related to preserved WM microstructure in the brain of MPS IH patients. Free water‐corrected DTI distinguishes severe and attenuated MPS I patients and reveals a relationship between attention, age at HSCT, and white matter microstructure.


  • Open Access

    Early Neonatal Cardiac Phenotype in Hurler Syndrome: Case Report and Literature Review

    by Nishitha R. Pillai, Alia Ahmed, Todd Vanyo, Chester B. Whitley

    Mucopolysaccharidosis type I (MPS I) is a rare inherited lysosomal disorder caused by deficiency of the α-L-iduronidase enzyme, resulting in the progressive accumulation of glycosaminoglycans (GAGs), which interfere with the normal function of multiple tissues and organs. The clinical phenotype includes characteristic facial features, hepatosplenomegaly, dysostosis multiplex, umbilical and inguinal hernias, progressive cognitive deficits with corresponding hydrocephalus, and neuropathology. Untreated children do not survive into the second decade. The common cardiac phenotype seen in MPS I and other MPS types includes valve thickening and dysfunction, conduction abnormalities, coronary artery disease, and cardiomyopathy—usually seen later in the disease course. A 15-month-old ex-35-weeker who presented with cardiomyopathy and left ventricular failure at the age of three weeks is presented here. Early evaluation and diagnosis with the help of newborn screening (NBS), followed by treatment with enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), resulted in improvement of his cardiopulmonary status. In MPS I, an early cardiac phenotype is uncommon. Based on the evidence from the literature review for early neonatal cardiac phenotype, we propose that all infants with abnormal newborn screening for MPS I should receive cardiac screening with echocardiogram and NT-proB-type natriuretic peptide (BNP) during the initial evaluation.


  • Contribution of the innate and adaptive immune systems to aortic dilation in murine mucopolysaccharidosis type I

    by Elizabeth Braunlin, Juan E. Abrahante, Ron McElmurry, Michael Evans, Miles Smith, Davis Seelig, M. Gerard O'SUllivan, Jakub Tolar, Chester B. Whitley, R. Scott McIvor


  • Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I

    by Victor Kovac, Elsa G. Shapiro, Kyle D. Rudser, Bryon A. Mueller, Julie B. Eisengart, Kathleen A. Delaney, Alia Ahmed, Kelly E. King, Brianna D. Yund, Morton J. Cowan, et al.


  • Open Access

    Identification of a Novel Fusion Iduronidase with Improved Activity in the Cardiovascular System

    by Sarah Kim, Michael John Przybilla, Chester Buchan Whitley, Li Ou, Mahmoud Al-Kofahi, Jeanine Renae Jarnes

    Background: Lysosomal diseases are a group of over 70 rare, genetic diseases that commonly lead to enzyme deficiency and multi-systemic disorders. Currently, only 12 lysosomal diseases have approved treatments, and current therapies have difficulty reaching certain tissues that are major contributors to morbidity and mortality, such as the central nervous system (CNS) and cardiac valves. Therefore, the objective of this study was to improve the delivery of therapeutic enzymes, via gene therapy, to targeted tissues in lysosomal diseases. The lysosomal disease mucopolysaccharidosis type I (MPS I) was selected as the disease model. In MPS I, mutations in the IDUA gene cause a deficiency of the α-L-iduronidase (IDUA) enzyme, leading to disease pathology in tissues throughout the body, including the CNS and cardiac valves. Current therapies have been unable to prevent neurodevelopmental deficits and cardiac valvular disease in patients with MPS I.Methods: MPS I mice were hydrodynamically injected with plasmids containing either a codon-optimized cDNA encoding the IDUA protein or one of four modified IDUAs. Two modified IDUAs contained a ligand for the CB1 receptor, which is a highly expressed receptor in the CNS. Iduronidase activity levels were measured in the tissues and plasma using an enzyme activity assay.Results: The modified IDUAs did not appear to have improved activity levels in the brain compared with the unmodified IDUA. However, one modified IDUA exhibited higher activity levels than the unmodified IDUA in the heart (p=0.0211). This modified iduronidase (LT-IDUA) contained a sequence for a six amino acid peptide termed LT. LT-IDUA was further characterized using a noncompartmental pharmacokinetic approach that directly analyzed enzyme activity levels after gene delivery. LT-IDUA had a 2-fold higher area under the curve (AUC) than the unmodified IDUA (p=0.0034) when AUC was estimated using enzyme activity levels in the plasma.Conclusion: The addition of a six amino acid peptide improved iduronidase’s activity levels in the heart and plasma. The short length of this LT peptide facilitates its use as fusion enzymes encoded as gene therapy or administered as enzyme replacement therapy. More broadly, the LT peptide may aid in developing therapies for numerous lysosomal diseases.

  • Open Access

    A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A

    by Frits A. Wijburg, Chester B. Whitley, Joseph Muenzer, Serena Gasperini, Mireia del Toro, Nicole Muschol, Maureen Cleary, Caroline Sevin, Elsa Shapiro, David Alexanderian


  • Open Access

    The juvenile gangliosidoses: A timeline of clinical change

    by Kelly E. King, Sarah Kim, Chester B. Whitley, Jeanine R. Jarnes-Utz


  • Open Access

    The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII

    by Raymond Y. Wang, José Francisco da Silva Franco, Jaime López-Valdez, Esmeralda Martins, Vernon Reid Sutton, Chester B. Whitley, Lin Zhang, Tricia Cimms, Deborah Marsden, Agnieszka Jurecka, et al.